CLIN CHEM LAB MED:急诊病人d -二聚体检测的诊断和预后价值

2019-11-03 MedSci MedSci原创

D-二聚体测量可提高血栓栓塞性疾病的排除率。

D-二聚体测量可提高血栓栓塞性疾病的排除率。然而,目前关于血栓栓塞性疾病的假阳性结果的风险及其预后价值知之甚少。在此,我们调查了影响d -二聚体准确性的因素及其在急诊科(ED)患者中的预后价值。这是一项前瞻性观察性单中心队列研究的二级分析。包括治疗医师要求进行d -二聚体连续检测的病人。采用逻辑回归分析探讨入院时临床参数与d -二聚体假阳性诊断血栓栓塞性疾病的关系。

本研究共纳入3301例患者,其中203(6.1%)经确诊为血栓栓塞性疾病。 D-二聚体试验在0.5 mg / L临界值时的阴性和阳性预测值分别为99.9%和11.4%。 多种因素与D-二聚体阳性结果相关联,可能在多变量分析中错误地指示血栓栓塞性疾病,包括高龄(赔率[OR] 1.0495%置信区间[CI] 1.04–1.05p <0.001),充血性心力衰竭(CHF )(OR 2.7995CI 1.77–4.4p <0.01),肾衰竭(OR 2.0095CI 1.23–3.24p = 0.005),恶性病史(OR 2.695CI 1.57–4.31p <0.001),C反应蛋白(CRP)(OR 1.0295CI 1.01-1.02p <0.001)和肾小球滤过率(GFR)(OR 0.9995CI 0.99-1.00p = 0.003)。 关于其预后价值,D-二聚体与30天病死率相关(校正OR 1.0595CI 1.02-1.09p = 0.003),曲线下面积(AUC)为0.79

研究表明,虽然d -二聚体可以准确排除血栓栓塞性疾病,但其在常规ED患者中的阳性预测价值有限,且在很大程度上受年龄、共病和急性疾病因素的影响。d -二聚体在该人群中具有很强的预后价值,值得进一步研究。

原始出处:

Alaadin VögeliClaudia GregorianoDiagnostic and prognostic value of the D-dimer test in emergency department patients: secondary analysis of an observational study

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1950380, encodeId=218c195038085, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jun 24 21:21:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305191, encodeId=e7d01305191e6, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385230, encodeId=347513852304c, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610091, encodeId=31af161009101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2020-06-24 hxj0117
  2. [GetPortalCommentsPageByObjectIdResponse(id=1950380, encodeId=218c195038085, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jun 24 21:21:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305191, encodeId=e7d01305191e6, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385230, encodeId=347513852304c, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610091, encodeId=31af161009101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
    2019-11-05 marongnuan
  3. [GetPortalCommentsPageByObjectIdResponse(id=1950380, encodeId=218c195038085, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jun 24 21:21:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305191, encodeId=e7d01305191e6, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385230, encodeId=347513852304c, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610091, encodeId=31af161009101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1950380, encodeId=218c195038085, content=<a href='/topic/show?id=bfc624041dc' target=_blank style='color:#2F92EE;'>#二聚体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=24041, encryptionId=bfc624041dc, topicName=二聚体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Wed Jun 24 21:21:00 CST 2020, time=2020-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305191, encodeId=e7d01305191e6, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385230, encodeId=347513852304c, content=<a href='/topic/show?id=dc121001e22d' target=_blank style='color:#2F92EE;'>#预后价值#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100172, encryptionId=dc121001e22d, topicName=预后价值)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=70fe497, createdName=paperyu, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610091, encodeId=31af161009101, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Tue Nov 05 13:21:00 CST 2019, time=2019-11-05, status=1, ipAttribution=)]

相关资讯

BMJ Open:“新计算器”助力临床医师精准诊断糖尿病分型

精准确诊患者的糖尿病分型在糖尿病诊疗中举足轻重,是临床工作中的难点之一。由于患者临床特征的复杂性,尽管胰岛细胞相关的抗体检测、1型糖尿病遗传风险在一定程度上有助于诊断,却并不能做到精准诊断。 近期发表于BMJ OPEN杂志的一项研究显示一种在线使用的“新计算器”有助于快速诊断不同类型的糖尿病。

J Endod:牙列创伤的评估和诊断

外伤性牙齿损伤包括许多下班后或在牙科诊所环境中的非计划单会经常看到的牙科急诊患者。尽管有多种创伤性的牙齿损伤,但是每种自身的推荐治疗方案、外伤牙列最初的评估和诊断对于这些病例的处理占有极其重要的环节。

帕金森病前驱期诊断研究标准中国专家共识

帕金森病是老年人常见的神经系统退行性疾病,其典型病理改变为α一突触核蛋白聚集分布于全身多个器官和多巴胺能神经元缺失,从而导致运动和非运动症状。从患者出现第一个帕金森病非运动症状到符合临床诊断标准之间的前驱期阶段可长达20年。帕金森病病程发展不可逆,而目前所有药物和手术治疗均只能改善患者的临床症状,无法治愈疾病。已开展的针对发病患者的神经保护药物临床试验尚未获得确切的阳性结果,可能的原因之一是干预治

ARCH PATHOL LAB MED:SATB2与CDX2在黏液性肿瘤诊断优势的比较

转移性黏液性肿瘤对病理学家来说在诊断上存在一定的困难,因为肿瘤的组织形态学通常是非特异性的,有关其的免疫功能仍在研究中。

2019 ESPGHAN指南:乳糜泻的诊断

2019年9月,欧洲儿科胃肠病学、肝病学和营养协会(ESPGHAN)发布了乳糜泻的诊断指南。2012年ESPGHAN乳糜泻诊断指南的主要目的是为医生正确诊断乳糜泻并再选定的患者中进行十二指肠活检提供指导。本文是对该指南的更新,文章指出如果遵循相关建议,物理是否进行十二指肠活检都可以准确诊断乳糜泻。